Education
About Us
Working with TipRanks
Follow Us
Mabion SA (PL:MAB)
:MAB
MAB Stock Chart & Stats
zł8.02
--
Market closed
zł8.02
--
Day’s Range― - ―
52-Week Rangezł8.00 - zł16.36
Previous CloseN/A
VolumeN/A
Average Volume (3M)38.65K
Market Cap
€131.24M
Enterprise Valuezł152.41M
Total Cash (Recent Filing)€23.69M
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,162,327
10 Day Avg. Volume25,807
30 Day Avg. Volume38,648
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.29
Price to Sales (P/S)2.08
P/FCF Ratio5.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MAB FAQ
What was Mabion SA’s price range in the past 12 months?
Mabion SA lowest stock price was zł8.00 and its highest was zł16.36 in the past 12 months.
What is Mabion SA’s market cap?
Mabion SA’s market cap is €131.24M.
When is Mabion SA’s upcoming earnings report date?
Mabion SA’s upcoming earnings report date is May 21, 2026 which is in 194 days.
How were Mabion SA’s earnings last quarter?
Currently, no data Available
Is Mabion SA overvalued?
According to Wall Street analysts Mabion SA’s price is currently Overvalued.
Does Mabion SA pay dividends?
Mabion SA does not currently pay dividends.
What is Mabion SA’s EPS estimate?
Mabion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mabion SA have?
Mabion SA has 16,162,327 shares outstanding.
What happened to Mabion SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mabion SA?
Currently, no hedge funds are holding shares in PL:MAB
Company Description
Mabion SA
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
Technical Analysis
Ryvu Therapeutics SA
―
Scope Fluidics SA
―
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
―
Captor Therapeutics SA
―
OncoArendi Therapeutics SA
―